2-BROMO-4-FLUORO-6-NITROTOLUENE Chemical Properties

Boiling point:

259.4±35.0 °C(Predicted)

Density 

1.696±0.06 g/cm3(Predicted)

storage temp. 

Sealed in dry,Room Temperature

form 

fused chunks crystalline powder

color 

Faint lime fused chunks

InChI

InChI=1S/C7H5BrFNO2/c1-4-6(8)2-5(9)3-7(4)10(11)12/h2-3H,1H3

InChIKey

ZVDFTBJXUXQPAU-UHFFFAOYSA-N

SMILES

C1(Br)=CC(F)=CC([N+]([O-])=O)=C1C

Safety Information

Hazard Codes 

Xi

Hazard Note 

Irritant

HS Code 

2904990090

2-BROMO-4-FLUORO-6-NITROTOLUENE Usage And Synthesis

Uses

2-Bromo-4-fluoro-6-nitrotoluene is a pharmaceutical intermediate for the preparation of Remibrutinib. Remibrutinib is used for the treatment of chronic urticaria or urticaria and is currently in clinical development.

Synthesis

Step 23a: 3-bromo-5-fluoro-2-methylaniline (Compound 0104-69) was added to a solution of trifluoroacetic acid (40 mL) containing 4-fluoro-2-nitrotoluene (10.0 g, 64.4 mmol). Subsequently, sulfuric acid (12.5 mL) was added slowly and N-bromosuccinimide (NBS, 17.2 g, 96.6 mmol) was added in batches. The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the mixture was slowly poured into ice water and stirring was continued for 15 min. Extraction was carried out with ethyl acetate, the organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the target product 1-bromo-5-fluoro-2-methyl-3-nitrobenzene (15.0 g, 100% yield) as a yellow oil. The product was characterized by 1H NMR (400 MHz, DMSO-d6): δ 2.41 (s, 3H), 7.96 (dd, J = 8.0,2.4Hz, 1H), 8.02 (dd, J = 8.0,2.4Hz, 1H).

References

[1] Patent: WO2011/130628, 2011, A1. Location in patent: Page/Page column 155
[2] Patent: US2013/102595, 2013, A1. Location in patent: Paragraph 0279; 0280
[3] Patent: JP2015/187145, 2015, A. Location in patent: Paragraph 0252
[4] Patent: WO2007/122410, 2007, A1. Location in patent: Page/Page column 66
[5] Patent: WO2008/152387, 2008, A1. Location in patent: Page/Page column 33